SOLIRIS in Slovenian translation

• zdravilo soliris
• zdravilom soliris
• zdravila soliris

Examples of using Soliris in English and their translations into Slovenian

Soliris is used to treat adults
Zdravilo Soliris se uporablja za zdravljenje odraslih

At least 14 days before you start treatment with Soliris, your doctor will administer a vaccine against meningitis if it was not previously administered or if your vaccination is outdated.
Najkasneje 14 dni pred začetkom zdravljenja z zdravilom Soliris vas bo zdravnik cepil proti meningitisu, če še niste bili cepljeni ali če cepljenje ne učinkuje več.

Soliris must be administered by a healthcare professional
Zdravilo Soliris mora dajati zdravstveni delavec,

Patients in both prospective studies were treated with Soliris for 26 weeks and most patients enrolled into a long-term, open-label extension study.
Bolniki iz obeh prospektivnih študij so bili 26 tednov zdravljeni z zdravilom Soliris in vsi bolniki so bili vključeni v dolgotrajen, odprt podaljšek študije.

In paediatric PNH and aHUS patients with body weight below 40 kg, the Soliris dosing regimen consists of.
Pri pediatričnih bolnikih s PNH in z aHUS s telesno maso manj kot 40 kg je shema odmerjanja zdravila Soliris sestavljena iz.

Soliris must be given under the supervision of a doctor who has experience in the management of patients with blood and/or kidney disorders.
Zdravilo Soliris se mora dajati pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem bolnikov s krvnimi in/ali ledvičnimi obolenji.

There is no evidence to suggest that any special precautions are needed when older people are treated- although experience with Soliris in this patient population is still limited.
Ni dokazov, da bi bili pri zdravljenju starejših ljudi potrebni posebni previdnostni ukrepi- čeprav so izkušnje z zdravilom Soliris pri tej populaciji bolnikov še vedno omejene.

Cases of thrombotic microangiopathy complication have been reported in the setting of missed or delayed Soliris dose in aHUS clinical trials(see also Section 4.4).
Poročali so o primerih zapleta trombotične mikroangiopatije pri izpuščenem odmerku ali nepravočasnem dajanju odmerka zdravila Soliris v kliničnih preskušanjih aHUS(glejte tudi poglavje 4.4).

Soliris reduced signs of complement-mediated TMA activity,
Zdravilo Soliris je zmanjšalo znake aktivnosti TMA,

Soliris treatment is recommended to continue for the patient's lifetime, unless the discontinuation of Soliris is clinically indicated(see section 4.4).
Priporočeno je, da se bolnik z zdravilom Soliris zdravi celo življenje, razen če je prekinitev zdravljenja z zdravilom Soliris klinično indicirana(glejte poglavje 4.4).

Soliris was studied in one main study involving 87 adults with PNH who had had at least four blood transfusions for anaemia in the previous year.
Zdravilo Soliris so proučevali v eni glavni študiji s 87 odraslimi bolniki s paroksizmalno nočno hemoglobinurijo, ki so v preteklem letu zaradi slabokrvnosti prejeli najmanj štiri transfuzije krvi.

up to 127 weeks following discontinuation of Soliris treatment in some patients.
so pri nekaterih bolnikih opazili že 4 tedne in do 127 tednov po prekinitvi zdravljenja z zdravilom Soliris.

Dilute Soliris to a final concentration of 5 mg/ml(initial concentration divided by 2)
Zdravilo Soliris razredčite do končne koncentracije 5 mg/ml(začetna koncentracija, deljena z dva)

Antibodies to Soliris were detected in 2% of patients with PNH using an ELISA assay
Protitelesa proti zdravilu Soliris so bila ugotovljena pri 2% bolnikov s PNH s testom ELISA

Physicians must discuss the benefits and risks of Soliris therapy with patients and provide them with
Zdravniki se morajo z bolniki pogovoriti o koristih in tveganjih zdravljenja z zdravilom Soliris in jih oskrbeti z brošuro z informacijami za bolnike

Prior to initiating Soliris therapy, it is recommended that PNH
Pred začetkom zdravljenja z zdravilom Soliris je priporočljivo, da bolniki s PNH

Renal function, as measured by eGFR, was improved and maintained during Soliris therapy.
Med zdravljenjem z zdravilom Soliris se je izboljšalo in ostalo izboljšano delovanje ledvic, ki ga merimo z eGFR.

Soliris is not expected to affect the aplastic component of anaemia in patients with PNH.
Ni pričakovati, da bi zdravilo Soliris vplivalo na aplastično komponento anemije pri bolnikih s PNH.

Prior to initiating Soliris therapy, it is recommended that PNH patients should receive immunizations according to current immunization guidelines.
Pred začetkom zdravljenja z zdravilom Soliris je priporočljivo, da bolniki s PNH prejmejo imunizacije v skladu z veljavnimi smernicami o imunizaciji.

NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Soliris 300 mg concentrate for solution for infusion Eculizumab For intravenous use.
Soliris 300 mg koncentrat za pripravo raztopine za infundiranje Ekulizumab Za intravensko uporabo.